Lowering immunosuppression after liver transplant with everolimus
Treatments studied
Part of Immune system & allergy clinical trials.
This study tests whether adding the drug everolimus can safely reduce the amount of tacrolimus (an anti-rejection medicine) needed after a first liver transplant. This may help protect your kidneys while still preventing organ rejection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old and have received your first liver transplant only (no other organ transplants).
- Your kidney function must be adequate (eGFR of 30 or higher).
- You must currently be taking tacrolimus, with or without other standard anti-rejection drugs.
- If you are of childbearing age, you need a negative pregnancy test and must agree to use birth control during the study.
- You must have been vaccinated or have documented immunity to certain infections (like chickenpox, measles, hepatitis B, flu, shingles, and COVID-19).
- You must not have any active infections, certain autoimmune liver diseases, or a history of serious rejection after your transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether a combination of two drugs, everolimus and epoetin, can help liver transplant recipients gradually reduce their anti-rejection medicines. If successful, it may lead to long-term transplant tolerance with fewer side effects.
This trial tests whether older kidney transplant recipients can safely reduce their immunosuppression medications using a special monitoring tool called Trugraf. If you are over 55, have had a stable transplant, and want to possibly lower your medications, this study may be for you.
This trial studies whether everolimus, a transplant medicine, can safely reduce the chance that liver cancer comes back after liver transplant. It compares how well the treatment works while carefully monitoring side effects and safety.
This trial tests whether switching from a standard anti-rejection medicine to a different one (everolimus) about a year after a liver transplant can help protect your new liver with fewer side effects. If you qualify, you will be monitored closely for a few years to see how well the new medicine works for you.
This trial studies whether everolimus can improve outcomes for people whose kidney transplant biopsy shows signs of a specific type of immune attack. It focuses on patients without certain antibodies and with particular biopsy findings, aiming to prevent rejection-related injury while balancing medication side effects.
This trial tests whether safely lowering the dose of tacrolimus—an anti-rejection drug—can still protect a kidney transplant one year after surgery. It's for first-time transplant recipients with low immune risk.
Hear when a new Liver Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.